Perry Capital Partners

ShareBite Inc., founded in 2014 and based in New York, operates a mobile application for corporate meal benefits. It facilitates team orders, flexible solutions, centralized allowances, and curated restaurant choices for employees of leading companies across various sectors. Notably, ShareBite integrates social impact by donating a meal to local hunger relief initiatives like Feeding America and City Harvest for every transaction made on its platform.

Loadsmart is a logistics technology company that provides an online platform for shippers and carriers to quote, book, and track freight. The platform aims to move freight quickly and efficiently by offering real-time quotes, automated pricing, and streamlined shipper-carrier interactions. By leveraging technology and logistics data, Loadsmart seeks to optimize pricing, booking, and shipment visibility, delivering transparent, reliable freight services to shippers and carriers. Founded in 2014, the company is based in Chicago, Illinois.

Loadsmart is a logistics technology company that provides an online platform for shippers and carriers to quote, book, and track freight. The platform aims to move freight quickly and efficiently by offering real-time quotes, automated pricing, and streamlined shipper-carrier interactions. By leveraging technology and logistics data, Loadsmart seeks to optimize pricing, booking, and shipment visibility, delivering transparent, reliable freight services to shippers and carriers. Founded in 2014, the company is based in Chicago, Illinois.

Capital Factors is an innovative and leading provider of factoring, credit protection, accounts receivable collection services.

Palatin Technologies is a biopharmaceutical company focused on developing targeted, receptor-specific peptide therapeutics. Its work centers on modulating melanocortin receptor and natriuretic peptide receptor systems to treat diseases with unmet medical needs and commercial potential. The lead product is Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The company is developing several additional candidates, including PL8177 (oral and systemic) targeting inflammatory and ocular conditions, such as non-infectious uveitis and dry eye disease; PL9643, a multi-receptor melanocortin agonist for ocular inflammation; PL3994, an NPR-A agonist for cardiovascular indications; and PL5028, a dual NPR-A/NPR-C agonist for cardiovascular and fibrotic diseases. It also explores indications in obesity, erectile dysfunction, pulmonary diseases, and other inflammatory conditions, leveraging melanocortin pathways to modulate inflammation and healing.